Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

<jats:title>ABSTRACT</jats:title><jats:p>Testing of<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Cryptococcus neoformans</jats:named-content>for susceptibility to antifungal drugs by standard microtiter methods has not been shown to correlate with clinical outcomes. This report describes a modified quantitative broth macrodilution susceptibility method showing a correlation with both the patient's quantitative biological response in the cerebrospinal fluid (CSF) and the survival of 85 patients treated with amphotericin B (AMB). The Spearman rank correlation between the quantitative<jats:italic>in vitro</jats:italic>measure of susceptibility and the quantitative measure of the number of organisms in the patient's CSF was 0.37 (<jats:italic>P</jats:italic>&lt; 0.01; 95% confidence interval [95% CI], 0.20, 0.60) for the first susceptibility test replicate and 0.46 (<jats:italic>P</jats:italic>&lt; 0.001; 95% CI, 0.21, 0.62) for the second susceptibility test replicate. The median<jats:italic>in vitro</jats:italic>estimated response (defined as the fungal burden after AMB treatment) at 1.5 mg/liter AMB for patients alive at day 14 was 5 CFU (95% CI, 3, 8), compared to 57 CFU (95% CI, 4, 832) for those who died before day 14. These exploratory results suggest that patients whose isolates show a quantitative<jats:italic>in vitro</jats:italic>susceptibility response below 10 CFU/ml were more likely to survive beyond day 14.</jats:p>

Original publication

DOI

10.1128/aac.00034-11

Type

Journal article

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

12/2011

Volume

55

Pages

5624 - 5630